SRP-9001 Benefits Duchenne Patients Originally Given Placebo in Trial

SRP-9001 Benefits Duchenne Patients Originally Given Placebo in Trial

315904

SRP-9001 Benefits Duchenne Patients Originally Given Placebo in Trial

Children with Duchenne muscular dystrophy (DMD) who had been given a placebo in a clinical trial experienced a marked improvement in motor abilities after being treated with Sarepta Therapeutics‘ experimental gene therapy SRP-9001, new top-line data show. “We are delighted to report positive results for Part 2 of our blinded, placebo-controlled Study 102 in Duchenne, where the 48-week functional benefits of SRP-9001 in patients dosed at cross-over were statistically significant when compared to pre-specified matched…

You must be logged in to read/download the full post.